Bavarian Nordic A/S (OTCMKTS:BVNRY) Sees Large Decline in Short Interest

Bavarian Nordic A/S (OTCMKTS:BVNRY) saw a significant decline in short interest during the month of April. As of April 30th, there was short interest totalling 100 shares, a decline of 87.5% from the April 15th total of 800 shares. Based on an average daily volume of 3,100 shares, the short-interest ratio is presently 0.0 days.

Bavarian Nordic A/S Trading Up 0.8 %

Shares of BVNRY traded up $0.06 during midday trading on Friday, hitting $7.73. 1,402 shares of the company’s stock traded hands, compared to its average volume of 1,596. The stock has a market capitalization of $1.81 billion, a price-to-earnings ratio of 12.26 and a beta of 1.50. Bavarian Nordic A/S has a 1 year low of $5.95 and a 1 year high of $10.65. The firm’s fifty day moving average is $7.48 and its 200-day moving average is $7.67.

Bavarian Nordic A/S (OTCMKTS:BVNRY) last announced its quarterly earnings data on Wednesday, March 6th. The company reported $0.56 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.12. Bavarian Nordic A/S had a return on equity of 16.11% and a net margin of 14.74%. The business had revenue of $353.27 million for the quarter, compared to analyst estimates of $340.71 million. On average, equities research analysts anticipate that Bavarian Nordic A/S will post 0.52 EPS for the current year.

About Bavarian Nordic A/S

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.